## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `article_bundle` — **LLM article bundle** Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. - **article slug:** `pt-141-glp1-gut` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system. - **read:** https://miscsubjects.com/api/articles/pt-141-glp1-gut/bundle?format=markdown ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-glp1-gut/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-glp1-gut/topology - **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/pt-141-glp1-gut/voxels - **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-glp1-gut/prompts - **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node. - **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/pt-141-glp1-gut/voxels - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.* --- # miscsubjects article bundle > Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest. ## MASTHEAD - **identity:** `pt-141-glp1-gut` v2 · content_hash `00318268f37a8e42…` · thread_head genesis · 30 DIVs - **thesis (c1):** Phase 2 BMT-801 trial showed co-administration of bremelanotide and tirzepatide met primary endpoint for weight loss with additive effects. - c2 [human/active] Bremelanotide can decrease gastric emptying and carries caution for use in patients with slow gastric emptying. - c3 [mechanistic/active] No human trials show PT-141 repairs GLP-1 induced gut damage or gastroparesis. - **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes - **standing objections:** 0 open → https://miscsubjects.com/api/articles/pt-141-glp1-gut/discourse - **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key - **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/pt-141-glp1-gut/discourse · https://miscsubjects.com/api/protocol ## Article - **slug:** `pt-141-glp1-gut` - **title:** PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways - **url:** https://miscsubjects.com/a/pt-141-glp1-gut - **register:** source_ledger - **updated:** 2026-07-17T02:41:06.245Z - **tags:** peptide, matrix ## Body ## What's breaking down if you have GLP-1 gut damage / gastroparesis GLP-1 agonists slow gastric emptying as part of their metabolic action. This can lead to delayed stomach emptying, nausea, bloating, and in some cases gastroparesis-like symptoms. The gut motility slowdown is a direct effect of the drug class rather than a separate disease process in most users. Repair pathways would focus on restoring normal motility and tissue resilience. Symptom suppression or drug pause addresses load but does not rebuild motility function. No matched condition profile existed in the ledger, so layers are inferred from the slug and available claims: slowed emptying, potential mucosal stress, and secondary effects on appetite signals. ## Why PT-141 might help you 1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name. 2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. PT-141 acts on melanocortin receptors, primarily MC4R in the central nervous system, to influence arousal pathways. If your GLP-1 experience includes reduced libido or sexual desire (a reported secondary effect in some users), this CNS layer could intersect. The compound does not target gastric motility repair directly. Any discussion stays at the sexual / CNS arousal layer per the enrichment brief. ## Why GLP-1 agonists (class) matters for you **Drug:** GLP-1 agonists (class) **What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss. **Therefore for you:** This drug suppresses appetite signals and slows gastric emptying, which supports metabolism but trades off by potentially worsening or causing gut motility issues. It reduces metabolic load through weight effects but does not support repair of the slowed emptying it induces. Recent phase 2 data explored co-administration with PT-141 for additive weight outcomes without increased gut tolerability problems in that specific study design. ## How these fit together Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. - **PT-141** → sexual / CNS arousal The fit centers on separate layers. GLP-1 provides metabolic support while introducing gut slowdown. PT-141 addresses arousal pathways independently. No direct synergy for gut tissue repair is mapped; the combination appears in obesity studies for weight endpoints rather than motility restoration. ## What the evidence actually shows Human data on PT-141 with GLP-1 agonists comes from one phase 2 obesity trial (BMT-801) using bremelanotide plus tirzepatide. The study met its primary endpoint for percent weight loss and showed additive effects plus reduced post-treatment weight regain compared to tirzepatide alone. Appetite suppression improved across arms. No specific endpoints for gastric emptying or gastroparesis repair were reported. (source s0, s1, s2, s7) PT-141 labeling and reviews note it can decrease gastric emptying, with cautions for use in patients with existing slow gastric emptying. This appears in prescribing information and multiple clinical summaries. (source s14, s15, s17) No human trials demonstrate PT-141 repairing GLP-1-induced gut damage. Preclinical data on melanocortin effects on gut motility are absent from searched results. Anecdotal reports link GLP-1 use to libido changes, with occasional mentions of PT-141 in context but no controlled data. Evidence inventory: 1 human phase 2 trial (obesity co-administration, n=96 randomized), multiple safety summaries on gastric effects (human labeling data), Reddit threads on GLP-1 libido and occasional PT-141 references (anecdotal). ## What scientists say Study authors from Palatin highlight synergistic weight loss and appetite control in the co-administration arm without added safety signals for the tested doses. The design was not optimized for gut repair endpoints. (source s0, s7) Prescribing information for bremelanotide explicitly flags caution in slow gastric emptying conditions due to further delay potential. (source s14) ## What people say on Reddit Users in GLP-1 communities report libido reduction while on agonists. A few threads mention PT-141 as a possible counter for desire effects, often in passing. No detailed reports of gut symptom improvement from PT-141 appear in searched results. One post notes pairing considerations but remains speculative. (source s10, s12, s13) ## What people say on X Limited direct posts in search scope. Discussions center on the obesity trial results rather than gut repair. No prominent user reports tying PT-141 to resolution of gastroparesis symptoms from GLP-1 use. ## What we do not know Whether PT-141 influences any repair pathway for GLP-1-delayed gastric emptying remains unknown. Long-term effects on gut motility when combined with GLP-1 agonists have not been studied. Human data separating arousal benefits from gut outcomes in this specific cross are absent. Dose-response for any motility interaction lacks dedicated trials. ## Safety and limits PT-141 carries known risks of nausea, flushing, headache, and transient blood pressure increases. It is contraindicated in uncontrolled hypertension. Labeling warns of potential worsening of slow gastric emptying. The phase 2 co-administration study reported no increase in tolerability issues at low doses tested, but this does not extend to gastroparesis repair claims. All use remains off-label for gut applications. Individual responses vary; monitoring for additive GI effects is prudent based on known mechanisms. ## Claims (3) - **c3** [mechanistic w=0.3] No human trials show PT-141 repairs GLP-1 induced gut damage or gastroparesis. - who_claims: grok/grok-4.3 - **c1** [human w=0.8] Phase 2 BMT-801 trial showed co-administration of bremelanotide and tirzepatide met primary endpoint for weight loss with additive effects. - who_claims: grok/grok-4.3 - sources: s0 - **c2** [human w=0.8] Bremelanotide can decrease gastric emptying and carries caution for use in patients with slow gastric emptying. - who_claims: grok/grok-4.3 - sources: s14 ## Voxel graph (3 atoms · 5 edges) - full graph: https://miscsubjects.com/api/articles/pt-141-glp1-gut/voxels ## Article constitution - full: https://miscsubjects.com/api/articles/constitution ## Source ledger (2) - chain valid: yes · head: `c613e26a32fd644a` ### s0 · news · ok - title: Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - url: https://palatin.com/press_releases/palatin-announces-mc4r-agonist-bremelanotide-co-administered-with-glp-1-gip-tirzepatide-meets-primary-endpoint-in-phase-2-obesity-study/ - summary: Phase 2 results on bremelanotide + tirzepatide for obesity. - quote: The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1 /GIP tirzepatide treatment. - claim_ids: c1 - hash: `41c499b11caea332` ### s14 · medical · http_403 - title: Bremelanotide (subcutaneous route) - url: https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805 - summary: Official caution on gastric effects. - quote: Stomach or bowel problem (eg, slow gastric emptying)—Use with caution. May make this condition worse and decrease the absorption of oral medicines. - claim_ids: c2 - hash: `c613e26a32fd644a` ## Provenance (2 model passes) - chain valid: yes · head: `1c21eabb6f6fb902` - write · grok/grok-4.3 · 2026-06-30T01:16 · hash `25030a002c15` - voxel_divide · owner · 2026-07-17T02:41 · hash `1c21eabb6f6f` ## Question graph - questions: 0 · evidence ingests: 0 ## LLM manifest — how to communicate with this ledger - system map: https://miscsubjects.com/api/articles/system-map?format=markdown - topology (ranked): https://miscsubjects.com/api/articles/pt-141-glp1-gut/topology - ingest: POST https://miscsubjects.com/api/protocol/ingest - claim: POST https://miscsubjects.com/api/protocol/claim ### Quick actions for this article - **Read live:** https://miscsubjects.com/api/articles/pt-141-glp1-gut/topology - **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"pt-141-glp1-gut","question":"..."}` - **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest pt-141-glp1-gut|your evidence` - **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim pt-141-glp1-gut|tier|assertion` - **iMessage ask:** `pt-141-glp1-gut|your question` - **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown --- ## §SELF — miscsubjects portable reference **Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next. **This widget:** `system_map` — **System map** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **article slug:** `pt-141-glp1-gut` - **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest - **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context. - **read:** https://miscsubjects.com/api/articles/system-map ### Logical proof (verify each step) 1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution 2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-glp1-gut/sources 3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol 4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow 5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex 6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map ### Related features (explains other parts of the system) - **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution - **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest - **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip - **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip - **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-glp1-gut/bundle?format=markdown - **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown ### Full index - JSON: https://miscsubjects.com/api/articles/system-map - Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown ### §STRUCTURE This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure ### §INTEGRITY Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you. ### §GAUNTLET Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted. *Not medical advice. Tier-honest. Cite claim/source ids.*